|
 |
|
Please see our Calendar for a current listing of seminars and events...click
CNRS 5227
Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA.Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.Lancet Neurol. 2009 Dec;8(12):1128-39
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.Lancet Neurol. 2009 Dec;8(12):1140-9
Rotge JY, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aouizerate B, Burbaud P. Gray Matter Alterations in ObsessiveCompulsive Disorder: An Anatomic Likelihood Estimation MetaAnalysis.
Neuropsychopharmacology. 2009 Nov 4.
Sole G, Ferrer X, Vital C, Martin Negrier ML, Vital A, Latour P. Ultrastructural mitochondrial modifications characteristic of mitofusin 2 mutations (CMT2A).
J Peripher Nerv Syst. 2009 Sep;14(3):206-7
Cnrs 5231
Johnson EI, Sibon I, Renou P, Rouanet F, Allard M, Swendsen J.Feasibility and validity of computerized ambulatory monitoring in stroke patients.Neurology. 2009 Nov 10;73(19):1579-83
Cochet H, Couderc S, Pelé E, Amoretti N, Moreau-Durieux MH, Hauger O.Rotator cuff tears: should abduction and external rotation (ABER) positioning be performed before image acquisition? A CT arthrography study.Eur Radiol. 2009 Nov 5.
|
|
|
The overarching goal of the Symposia of the Bordeaux Neurosciences Institute is to bring locally a selected set of top researchers on a scientific topic that is of broad interest to the community. There will be 2-3 symposia per year, with each symposium lasting 1 or 2 days. Symposia are open to everyone from Bordeaux and outside, and are free."
International Symposium on New Therapeutic Avenues in Parkinson’s Disease and Related Disorders, Bordeaux, France, Bordeaux University, May 5 - 6 , 2010. The objective of this meeting is to brainstorm and dialogue between international Parkinson’s disease experts and representatives of leading healthcare companies and innovative biotech startups, to better understand the evolution of the therapeutic area (met versus unmet needs, clinical trial design, derisking translational development, emerging treatment challenges) and its strategic implications for the Healthcare industry.
|
